
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Korys Investments
Deal Size : $22.5 million
Deal Type : Financing
Commit Biologics Receives €5.5M Investment to Develop Bispecific Platform
Details : The proceeds from the financing, which will be used to advance the BiCE platform and work towards drug candidate selection for cancer and autoimmune disease treatments.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 28, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Korys Investments
Deal Size : $22.5 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Bioqube Ventures
Deal Size : $17.2 million
Deal Type : Financing
Commit Biologics Launches with €16M Seed Financing for Cancer and Autoimmune Disease
Details : Commit is advancing its BiCE™ platform using single domain antibodies to activate the complement system for cancer and autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Bioqube Ventures
Deal Size : $17.2 million
Deal Type : Financing
